Cargando…

Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis

INTRODUCTION: We previously demonstrated that HER2/neu-driven mammary carcinogenesis can be prevented by an interleukin-12 (IL-12)-adjuvanted allogeneic HER2/neu-expressing cell vaccine. Since IL-12 can induce the release of interleukin-15 (IL-15), in the present study we investigated the role playe...

Descripción completa

Detalles Bibliográficos
Autores principales: Croci, Stefania, Nanni, Patrizia, Palladini, Arianna, Nicoletti, Giordano, Grosso, Valentina, Benegiamo, Giorgia, Landuzzi, Lorena, Lamolinara, Alessia, Ianzano, Marianna L., Ranieri, Dario, Dall’Ora, Massimiliano, Iezzi, Manuela, De Giovanni, Carla, Lollini, Pier-Luigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4462012/
https://www.ncbi.nlm.nih.gov/pubmed/25997501
http://dx.doi.org/10.1186/s13058-015-0588-x
_version_ 1782375594529390592
author Croci, Stefania
Nanni, Patrizia
Palladini, Arianna
Nicoletti, Giordano
Grosso, Valentina
Benegiamo, Giorgia
Landuzzi, Lorena
Lamolinara, Alessia
Ianzano, Marianna L.
Ranieri, Dario
Dall’Ora, Massimiliano
Iezzi, Manuela
De Giovanni, Carla
Lollini, Pier-Luigi
author_facet Croci, Stefania
Nanni, Patrizia
Palladini, Arianna
Nicoletti, Giordano
Grosso, Valentina
Benegiamo, Giorgia
Landuzzi, Lorena
Lamolinara, Alessia
Ianzano, Marianna L.
Ranieri, Dario
Dall’Ora, Massimiliano
Iezzi, Manuela
De Giovanni, Carla
Lollini, Pier-Luigi
author_sort Croci, Stefania
collection PubMed
description INTRODUCTION: We previously demonstrated that HER2/neu-driven mammary carcinogenesis can be prevented by an interleukin-12 (IL-12)-adjuvanted allogeneic HER2/neu-expressing cell vaccine. Since IL-12 can induce the release of interleukin-15 (IL-15), in the present study we investigated the role played by IL-15 in HER2/neu driven mammary carcinogenesis and in its immunoprevention. METHODS: HER2/neu transgenic mice with homozygous knockout of IL-15 (here referred to as IL15KO/NeuT mice) were compared to IL-15 wild-type HER2/neu transgenic mice (NeuT) regarding mammary carcinogenesis, profile of peripheral blood lymphocytes and splenocytes and humoral and cellular responses induced by the vaccine. RESULTS: IL15KO/NeuT mice showed a significantly earlier mammary cancer onset than NeuT mice, with median latency times of 16 and 20 weeks respectively, suggesting a role for IL-15 in cancer immunosurveillance. Natural killer (NK) and CD8+ lymphocytes were significantly lower in IL15KO/NeuT mice compared to mice with wild-type IL-15. The IL-12-adjuvanted allogeneic HER2/neu-expressing cell vaccine was still able to delay mammary cancer onset but efficacy in IL-15-lacking mice vanished earlier: all vaccinated IL15KO/NeuT mice developed tumors within 80 weeks of age (median latency of 53 weeks), whereas more than 70 % of vaccinated NeuT mice remained tumor-free up to 80 weeks of age. Vaccinated IL15KO/NeuT mice showed less necrotic tumors with fewer CD3+ lymphocyes and lacked perforin-positive infiltrating cells compared to NeuT mice. Concerning the anti-vaccine antibody response, antibody titer was unaffected by the lack of IL-15, but less antibodies of IgM and IgG1 isotypes were found in IL15KO/NeuT mice. A lower induction by vaccine of systemic interferon-gamma (IFN-γ) and interleukin-5 (IL-5) was also observed in IL15KO/NeuT mice when compared to NeuT mice. Finally, we found a lower level of CD8+ memory cells in the peripheral blood of vaccinated IL15KO/NeuT mice compared to NeuT mice. CONCLUSIONS: We demonstrated that IL-15 has a role in mammary cancer immunosurveillance and that IL-15-regulated NK and CD8+ memory cells play a role in long-lasting immunoprevention, further supporting the potential use of IL-15 as adjuvant in immunological strategies against tumors. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13058-015-0588-x) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4462012
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-44620122015-06-11 Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis Croci, Stefania Nanni, Patrizia Palladini, Arianna Nicoletti, Giordano Grosso, Valentina Benegiamo, Giorgia Landuzzi, Lorena Lamolinara, Alessia Ianzano, Marianna L. Ranieri, Dario Dall’Ora, Massimiliano Iezzi, Manuela De Giovanni, Carla Lollini, Pier-Luigi Breast Cancer Res Research Article INTRODUCTION: We previously demonstrated that HER2/neu-driven mammary carcinogenesis can be prevented by an interleukin-12 (IL-12)-adjuvanted allogeneic HER2/neu-expressing cell vaccine. Since IL-12 can induce the release of interleukin-15 (IL-15), in the present study we investigated the role played by IL-15 in HER2/neu driven mammary carcinogenesis and in its immunoprevention. METHODS: HER2/neu transgenic mice with homozygous knockout of IL-15 (here referred to as IL15KO/NeuT mice) were compared to IL-15 wild-type HER2/neu transgenic mice (NeuT) regarding mammary carcinogenesis, profile of peripheral blood lymphocytes and splenocytes and humoral and cellular responses induced by the vaccine. RESULTS: IL15KO/NeuT mice showed a significantly earlier mammary cancer onset than NeuT mice, with median latency times of 16 and 20 weeks respectively, suggesting a role for IL-15 in cancer immunosurveillance. Natural killer (NK) and CD8+ lymphocytes were significantly lower in IL15KO/NeuT mice compared to mice with wild-type IL-15. The IL-12-adjuvanted allogeneic HER2/neu-expressing cell vaccine was still able to delay mammary cancer onset but efficacy in IL-15-lacking mice vanished earlier: all vaccinated IL15KO/NeuT mice developed tumors within 80 weeks of age (median latency of 53 weeks), whereas more than 70 % of vaccinated NeuT mice remained tumor-free up to 80 weeks of age. Vaccinated IL15KO/NeuT mice showed less necrotic tumors with fewer CD3+ lymphocyes and lacked perforin-positive infiltrating cells compared to NeuT mice. Concerning the anti-vaccine antibody response, antibody titer was unaffected by the lack of IL-15, but less antibodies of IgM and IgG1 isotypes were found in IL15KO/NeuT mice. A lower induction by vaccine of systemic interferon-gamma (IFN-γ) and interleukin-5 (IL-5) was also observed in IL15KO/NeuT mice when compared to NeuT mice. Finally, we found a lower level of CD8+ memory cells in the peripheral blood of vaccinated IL15KO/NeuT mice compared to NeuT mice. CONCLUSIONS: We demonstrated that IL-15 has a role in mammary cancer immunosurveillance and that IL-15-regulated NK and CD8+ memory cells play a role in long-lasting immunoprevention, further supporting the potential use of IL-15 as adjuvant in immunological strategies against tumors. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13058-015-0588-x) contains supplementary material, which is available to authorized users. BioMed Central 2015-05-22 2015 /pmc/articles/PMC4462012/ /pubmed/25997501 http://dx.doi.org/10.1186/s13058-015-0588-x Text en © Croci et al. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Croci, Stefania
Nanni, Patrizia
Palladini, Arianna
Nicoletti, Giordano
Grosso, Valentina
Benegiamo, Giorgia
Landuzzi, Lorena
Lamolinara, Alessia
Ianzano, Marianna L.
Ranieri, Dario
Dall’Ora, Massimiliano
Iezzi, Manuela
De Giovanni, Carla
Lollini, Pier-Luigi
Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis
title Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis
title_full Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis
title_fullStr Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis
title_full_unstemmed Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis
title_short Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis
title_sort interleukin-15 is required for immunosurveillance and immunoprevention of her2/neu-driven mammary carcinogenesis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4462012/
https://www.ncbi.nlm.nih.gov/pubmed/25997501
http://dx.doi.org/10.1186/s13058-015-0588-x
work_keys_str_mv AT crocistefania interleukin15isrequiredforimmunosurveillanceandimmunopreventionofher2neudrivenmammarycarcinogenesis
AT nannipatrizia interleukin15isrequiredforimmunosurveillanceandimmunopreventionofher2neudrivenmammarycarcinogenesis
AT palladiniarianna interleukin15isrequiredforimmunosurveillanceandimmunopreventionofher2neudrivenmammarycarcinogenesis
AT nicolettigiordano interleukin15isrequiredforimmunosurveillanceandimmunopreventionofher2neudrivenmammarycarcinogenesis
AT grossovalentina interleukin15isrequiredforimmunosurveillanceandimmunopreventionofher2neudrivenmammarycarcinogenesis
AT benegiamogiorgia interleukin15isrequiredforimmunosurveillanceandimmunopreventionofher2neudrivenmammarycarcinogenesis
AT landuzzilorena interleukin15isrequiredforimmunosurveillanceandimmunopreventionofher2neudrivenmammarycarcinogenesis
AT lamolinaraalessia interleukin15isrequiredforimmunosurveillanceandimmunopreventionofher2neudrivenmammarycarcinogenesis
AT ianzanomariannal interleukin15isrequiredforimmunosurveillanceandimmunopreventionofher2neudrivenmammarycarcinogenesis
AT ranieridario interleukin15isrequiredforimmunosurveillanceandimmunopreventionofher2neudrivenmammarycarcinogenesis
AT dalloramassimiliano interleukin15isrequiredforimmunosurveillanceandimmunopreventionofher2neudrivenmammarycarcinogenesis
AT iezzimanuela interleukin15isrequiredforimmunosurveillanceandimmunopreventionofher2neudrivenmammarycarcinogenesis
AT degiovannicarla interleukin15isrequiredforimmunosurveillanceandimmunopreventionofher2neudrivenmammarycarcinogenesis
AT lollinipierluigi interleukin15isrequiredforimmunosurveillanceandimmunopreventionofher2neudrivenmammarycarcinogenesis